Citations

Showing 10 of 108104 citations.

Abstract 12959: Clonal Hematopoiesis of Indeterminate Potential Predicts Incident Venous Thromboembolism in the UK Biobank Cohort
Satterfield, Benjamin A. , Kullo, Iftikhar, Satterfield, Benjamin A , Dikilitas, Ozan , Saadatagah, Seyedmohammad

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12959 Get It

Introduction: Clonal hematopoiesis of indeterminate potential (CHIP) refers to the formation of genetically distinct subpopulations of blood cells due to somatic mutations. CHIP is associated with a variety of adverse outcomes, including hematological cancers, cardiovascular disease, and death. We sought to investigate the association of CHIP with incident venous thromboembolism (VTE). Methods: We analyzed exome sequence data from 200,628 individuals in the UK Biobank cohort using Mutect2 to identify a prespecified list of somatic mutations in DNMT3A, TET2, and ASXL1, which are known genetic drivers of CHIP. CHIP was defined as harboring a somatic mutation at a variant allele fraction (VAF) ≥10% and individuals with VAF <2% were deemed as non-carriers. VTE was ascertained using verbal interview data and diagnostic/procedural codes and defined as a composite of the following: thrombophlebitis of deep veins of lower limbs, embolism/thrombosis of vena cava, pulmonary embolism, venous thrombectomy of lower limb veins or IVC filter insertion. We implemented a nested case-control design with incidence density sampling to identify incident cases and controls matched (1:8 ratio) for sex, smoking status, and history of malignancy at baseline. Conditional logistic regression analysis adjusted for age, BMI, and genetic ancestry was performed to assess the association between CHIP and incident VTE. Results: Among 200,628 individuals, we identified 3,885 individuals with CHIP at baseline and 748 incident VTE events during a median follow-up of 9.2 years. In 748 incident cases and 5984 matched controls, CHIP was associated with increased risk of incident VTE independent of conventional risk factors for VTE, namely, age, sex, BMI, smoking, and history of malignancy (incidence rate ratio [95% confidence interval]; 1.60 [1.04-2.46], p=0.032). When we restricted the cases to individuals with incident pulmonary embolism (n=441), we observed a stronger association with CHIP (1.80 [1.08-3.05], p=0.025). Conclusions: CHIP is associated with increased risk of VTE independent of history of malignancy and other conventional risk factors. The pathophysiological basis for this association needs further investigation.
Abstract 12955: Clonal Hematopoiesis of Indeterminate Potential: A Novel Risk Factor for Atrial Fibrillation in the UK Biobank Cohort
Satterfield, Benjamin A. , Kullo, Iftikhar, Satterfield, Benjamin A , Saadatagah, Seyedmohammad , Dikilitas, Ozan

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12955 Get It

Introduction: The prevalence of atrial fibrillation (AF) increases with age and inflammation plays a key pathophysiologic role. Somatic mosaicism increases with age and promotes inflammation. Therefore, we investigated whether Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a risk factor for incident AF. Methods: We assessed exome sequence (ES) data from 200,628 participants in the UK biobank. Using the Genome Analysis Toolkit pipeline, we ascertained a predefined list of CHIP mutations in DNMT3A , TET2 , and ASXL1 . CHIP was defined as variant allele frequency (VAF) >10% and those with VAF <2% served as controls. AF was ascertained based on self-report and ICD codes. Lone AF was defined as AF in the absence of heart failure, mitral stenosis, mitral valve repair/valvotomy/replacement, and congenital heart disease. Those with AF prior to or at the time of enrollment were excluded from analyses to ascertain incident events. Cox proportional hazard models adjusted for age, sex, self-reported race/ethnicity, diabetes, hypertension, smoking, and obesity were used to identify associations between CHIP and incident AF. Results: Of 200,628 participants, 3885 (1.9%) had CHIP. The number of participants with mutations in DNMT3A , TET2 , and ASXL1 was 2512, 1065, and 439, respectively. During a median follow-up of 9 years, 4,676 incident AF and 3,584 incident lone AF occurred. CHIP was an independent risk factor for developing incident AF and also for developing lone AF. CHIP in TET2 and ASXL1 but not DNMT3A was associated with AF ( Table 1 ). Conclusions: The presence of CHIP involving TET2 and ASXL1 is associated with an increased risk of incident AF including the subset with lone AF. Our findings reveal somatic mosaicism in blood cells to be a novel risk factor for AF.
Abstract 12924: CCL18 Promotes Effector Functions of Pro-Inflammatory Macrophages by Inactivating GSK-3β
Hu, Zhao‐Lan , Frye, Robert L. , Weyand, Cornelia M. , Zhao, Tuantuan V. , Berry, Gerald J. , Bernstein, Kenneth E. , Goronzy, Jörg J.

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12924 Get It

Background: The risk for cardiovascular disease is multifold higher in patients with the autoimmune disease rheumatoid arthritis, but underlying mechanisms remain poorly defined. We have explored whether patients with rheumatoid arthritis (RA) and patients with coronary artery disease (CAD) share pro-inflammatory effector cells that sustain tissue inflammation, thus maintaining synovial inflammation and atherosclerotic plaque formation. Methods: Tissue cytokines expressed in RA synovial lesions were analyzed by cytokine array technology. Cytokine production in macrophages was verified with RT-PCR, immunohistochemistry and flow cytometry. Mitochondrial function was evaluated by Seahorse analyzer. Results: In highly inflamed synovial tissues, 21 of 60 cytokines tested were significantly elevated, with the small cytokine CCL18 being strongly associated with tissue inflammation. Immunohistochemical examination assigned CCL18 to CD68 + tissue macrophages in both the atherosclerotic plaque and in rheumatoid synovitis. In monocyte-derived macrophages (MΦ), CCL18 enhanced production of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α and stimulated production of the tissue-injurious enzyme cathepsin K. Pro-inflammatory effector functions were linked to CCL18 induced activation of mitochondrial metabolism, quantified by oxygen consumption rates and generation of ATP. Macrophage stimulation with recombinant CCL18 resulted in the inactivating phosphorylation of the metabolic sensor GSK-3β. Immunoprecipitation experiments localized GSK-3β to the mitochondrial surface and imaging studies revealed excessive formation of mitochondria-endoplasmic reticulum connections in patient-derived CCL18 hi macrophages. Conclusions: Pro-inflammatory MΦ in CAD and RA patients share a metabolic profile of increased mitochondrial oxygen consumption and ATP production. Mitochondrial activation depends on inactivation of the metabolic sensor GSK-3β and promote pro-inflammatory effector functions, such as production of cytokines and proteases. Inhibiting GSK-3β activation provides a novel therapeutic strategy to suppress pro-inflammatory macrophages in CAD and RA.
Abstract 12557: Echo-Guided vs. Device-Based Strategies for Optimization of Cardiac Resynchronization Therapy and Long-Term Clinical Outcomes: A Meta-Analysis
Ali‐Ahmed, Fatima, Friedman, D. B. , LaPointe, Nancy M. Allen, Dalgaard, Frederik , Mulpuru, Siva K. , Jackson, Kevin , Sanders, Gillian D, Friedman, Daniel, Kosinski, Andrzej S. , Al‐Khatib, Sana M.

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12557 Get It

Introduction: CRT optimizations has the potential to improve the 30% non-response rate. Randomized trials (RCTs) comparing device and echo-guided CRT optimization have been overall small and results have been conflicting. Methods: We searched the EMBASE and MEDLINE databases from January 2008 through September 2020 for RCTs and prospective observational studies that randomized patients to either echo-guided or device-based CRT optimization. Included studies had to report on at least one of the following outcomes of interest: all-cause mortality, heart failure hospitalization (HFH), NYHA class improvement, mean EF at follow up, LVEDD, 6MWD, and QoL. A meta-analyses on the outcomes of interest was performed using random effects models. Results: We included seven RCTs representing a total of 2,730 patients. Of those, 1,113 patients were randomized to echo-guided optimization, and 1,617 were randomized to device-based optimization. The mean age of patients was 64.5 years, and they were predominantly men (60%). In the device-based optimization group, there was 93 deaths (5.7%) and 142 HFH (5.1%). In the echo-guided optimization group, there was 57 deaths (10.2%) and 112 HFH (12.4%). On random effects meta-analysis, the device-based optimization group had a lower rate of HFH compared with the echo-guided optimization group (OR 0.81, 95% CL 0.70-0.95, Figure). However, differences in the following outcomes between the two groups were not statistically significant: all-cause mortality, mean follow up EF, LVEDD, NYHA class improvement, 6MWD improvement range or QoL. Conclusions: This meta-analysis suggests that echo-guided optimization of CRT is equivalent to device-based optimization in relation to the clinical outcomes of death, EF, LVEDD, NYHA and 6MWD but suggests that device-related optimization could reduce HFH. The latter merits further investigation in relation to different device-base optimization algorithms.
Abstract 12187: Arrhythmia Substrate and Approaches for First-Time and Repeat Catheter Ablation in Patients With D-transposition of the Great Arteries and Atrial Baffles
Chiriac, Anca , Cheema, Kamal Preet P, Giardi, Davide , Espinosa, Samantha , Fitzgerald, Patrick , Perez-Downes, Julio , Phillips, Sabrina D. , Madhavan, Malini , Umadat, Goyal , Asirvatham, Samuel J. , McLeod, Christopher J.

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12187 Get It

Introduction: Atrial arrhythmias are common in patients with D-TGA and atrial switch. We sought to analyze the arrhythmia substrate and catheter ablation approaches and outcomes. Methods: We performed a retrospective review of all clinical and procedural data in patients with D-TGA followed at a large tertiary care center. Results: In a cohort of 152 patients (mean age 30±11 years), atrial tachycardia was present in 69(45%) patients. Ablations were performed in 39(26%) patients: macro-reentrant atrial flutter (N=37), atrial fibrillation (N=4), and focal automatic atrial tachycardia (N=3). Detailed electrophysiology study data was available for 34 patients. At first ablation (N=28), cavo-tricuspid isthmus dependent flutter (CTI, 23(82%)) was most common, followed by right atriotomy-related flutter (IART, 16(57%)) and focal atrial tachycardia (FAT, 1(3.5%)). Bidirectional CTI block often required ablation on both sides of the baffle to complete the isthmus line. Access to the pulmonary venous atrium was obtained in 82% of first-time ablations (via retrograde aortic access, 74%, baffle puncture, 6%, or baffle fenestration, 12%) and in 100% of redo procedures. The first ablation was acutely successful in 25 (89%) patients; the other 3 patients had either partial procedural success (1), failed ablation (1), or underwent an empirical ablation (1). Long-term arrhythmia recurrence occurred in 13(46%) after the first ablation and class III antiarrhythmic medications were utilized in 12 patients. At least one long-term recurrence occurred in 11(44%) patients. Importantly, clinical arrhythmia burden was significantly reduced post-ablation, with rare and short-limited episodes amenable to antiarrhythmic drugs or cardioversion. Repeat ablation was required in 3 cases. Long-term arrhythmia recurrence after a previously completed CTI line involved different arrhythmia mechanisms: scar-related reentry (80%) and automatic atrial tachycardia (40%). Conclusions: Atrial arrhythmia in patients with D-TGA often involves the CTI and atriotomy scars. Ablation of the CTI typically requires access to the pulmonary venous atrium to achieve bidirectional block. Despite late recurrence, the clinical arrhythmic burden is substantially improved.
Abstract 12158: Higher Body Mass Index is Associated With More Heart Failure-Related Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction
Haase, Christiane L. , Oral, Tuğçe Kalaycı , Varbo, Anette , Morgen, Camilla S. , Schnecke, Volker , Borlaug, Barry A.

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12158 Get It

Introduction: In people with heart failure (HF) with preserved ejection fraction (HFpEF), the associations between BMI, comorbidities and outcomes are not well-defined. This retrospective cohort study examined the association between BMI and hospitalizations in patients with HFpEF. Hypothesis: Higher BMI is associated with more HF-related hospitalizations and shorter time to HF-related hospitalization. Methods: Data for patients with BMI ≥25 kg/m 2 at the time of HFpEF diagnosis were extracted from LCED, a US claims-electronic medical record data set. Patients were categorized into 5 BMI groups: overweight and obesity classes I-IV (Figure A). Negative binomial and Cox proportional hazard models were used to estimate associations between BMI and number of HF-related hospitalizations and risk of HF-related hospitalization during follow-up. Analyses were adjusted for relevant baseline comorbidities, with age, sex and diabetes status as effect modifiers. Results: Among 4,975 patients, median age was 74 years and 57.5% were female. Compared with the overweight group, higher BMI groups had a lower median age (years: overweight 80; obesity III 68; obesity IV 64), fewer patients with cardiovascular (CV) history (overweight 81.0%; obesity III 77.0%; obesity IV 66.0%) and a greater proportion of female patients (overweight 56.4%; obesity III 57.9%; obesity IV 69.0%) (Figure A). Mean HF-related hospitalizations/100 patient-years was higher for obesity III (12) and IV (16) vs overweight (10) (effect of BMI: p=0.002; Figure B). The hazard ratio [95% CI] for HF-related hospitalization was 1.36 [0.97; 1.91] and 1.86 [1.32; 2.64] for obesity III and IV, relative to overweight (effect of BMI: p=0.010). Conclusions: Results suggest even though patients with HFpEF in higher BMI groups are younger and have less CV history at baseline, higher BMI is associated with greater burden of HF-related hospitalizations during follow-up, irrespective of age, sex and diabetes status.
Abstract 12087: Device-Related Infection Associated With Increased Mortality Risk in de novo Transvenous Implantable Cardioverter-Defibrillator Medicare Patients
Liu, Yiyan , Weiss, Raul, Mark, George E., Lambiase, Pier D. , Miller, Marc A. , Jacobsen, Caroline, Lambiase, Pier D , El‐Chami, Mikhael F. , Griffiths, Robert, Knight, Bradley P. , Biffi, Mauro , Probst, Vincent , Jacobsen, Caroline M., Baddour, Larry M.

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12087 Get It

Introduction: Device-related infection is estimated to occur in 1.9% of the Medicare patients with de novo transvenous (TV) implantable cardioverter-defibrillators (ICD) within 2 years post-implant. TV-ICD infection is a serious complication that frequently requires complete device removal for attempted cure, which can be associated with patient morbidity and mortality. The objective of this study is to expand on limited published data and assess mortality risk associated with TV-ICD infection in a large Medicare population with de novo TV-ICD implants. Methods: A survival analysis was conducted using 100% fee-for-service Medicare facility-level claims data to identify patients who underwent de novo TV-ICD implantation between 7/2016 and 1/2018. TV-ICD infection within 2 years of implantation was identified using ICD-10 and CPT codes. Baseline patient risk factors associated with mortality were identified using the Charlson Comorbidity Index categories. Infection was treated as a time-dependent variable in a multivariate Cox proportional hazards model to account for immortal time bias. Results: Among 26,742 Medicare patients with de novo TV-ICD, 518 (1.9%) had a device-related infection. The overall number of decedents was 4,721 (17.7%) over 2 years, with 4,555 (17%) in the non-infection group and 166 (32%) in the infection group. After adjusting for baseline patient demographic characteristics and various comorbidities, the presence of TV-ICD infection was associated with an increase of 2.4 [95% CI: 2.08-2.85] times in the mortality hazard ratio (see attached Figure). Most of the baseline patient risk factors were also associated with higher risk of mortality in the Cox model. Conclusion: The rate of de novo TV-ICD infection and associated mortality in a large, real-world Medicare population is noteworthy. The positive association between device-related infection and risk of mortality further highlights the need to reduce infections.
Abstract 12076: Whole Genome Sequencing Association Study for Coronary Heart Disease in a Middle Eastern Cohort Validates Polygenic Risk Scores and Replicates Known Loci
Kunji, Khalid , Saad, Mohamad , Ullah, Ehsan , El‐Menyar, Ayman , Kullo, Iftikhar J. , Suwaidi, Jassim Al

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12076 Get It

Introduction: The potential use of polygenic risk scores (PRSs) in clinical practice is tempered by concern about their portability among diverse populations. To prevent disparities in genomic medicine, there is an urgent need to conduct genome-wide association studies in non-European ancestry cohorts. Methods: We conducted whole genome sequencing (WGS) with 30x coverage on coronary heart disease patients (n=1,067, mean age ± SD = 59.96 years ± 10.99; 70.32% males) and controls (n=6,170, mean age ± SD = 40.02 years ± 12.56; 43.45% males) in a Middle Eastern cohort to compare the performance of available PRSs for CHD (LDpred, metaGRS, lassosum, and P+T) and identify common variants associated with CHD (via generalized linear mixed models). Results: Excepting lassosum, all PRSs performed well. LDpred and metaGRS performed similarly (AUC= ~0.685) and outperformed P+T (AUC=0.667). Based on the OR per 1 SD increase (OR 1sd ), P+T (OR 1sd =1.85 [1.69-2.02], P =3.69x10 -41 ) outperformed other PRSs (OR 1sd =1.61 [1.48-1.74], P =3.02x10 -31 for LDpred and OR 1sd =1.61 [1.49-1.75], P =9.47x10 -31 for metaGRS). After binning PRSs into 10 deciles, the odds of CHD in the top decile compared to all others was highest for metaGRS (3.87 [3.07-4.88]) and LDpred (3.45 [2.74-4.341]). Thirty-two known GWAS loci (e.g., ABCG8 , CELSR2 , and SLC22A4 ) were replicated in our analysis with P <0.05. Seven suggestive new loci/genes ( P <10 -6 ) with relevant biological function were identified (e.g., CORO7 , RBM47 , and PDE4D ). The well-established 9p21 locus was not replicated. Conclusions: Genome-wide PRSs derived from European ancestry cohorts performed well in a Middle Eastern cohort. Further studies are needed to develop and validate an ancestry specific PRS and to confirm the suggestive loci/genes.
Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection
Niesen, Michiel J.M. , Matson, Robert P. , Puranik, Arjun, O’Horo, John C. , Pawlowski, Colin , Vachon, Celine M, Virk, Abinash , Swift, Melanie D. , Speicher, Leigh L. , Gordon, Joel , Geyer, Holly L. , Vachon, Celine, Challener, Douglas , Swift, Melanie, Speicher, Leigh, Geyer, Holly, Lenehan, Patrick J , Soundararajan, Venky , Badley, Andrew, O'Horo, John C , Swift, Melanie D , Challener, Douglas W. , Lenehan, Patrick J. , Venkatakrishnan, A J , Soundararajan, Venky , Badley, Andrew D.

Mayo Clinic

PNAS Nexus | April 28, 2022 | Volume: 1 | Issue: 2 | Pages: No page available

10.1093/pnasnexus/pgac042 | PMID 36713312 Get It

Abstract As of 2021 November 29, booster vaccination against SARS-CoV-2 infection has been recommended for all individuals aged 18 years and older in the United States. A key reason for this recommendation is the expectation that a booster vaccine dose can alleviate observed waning of vaccine effectiveness (VE). Although initial reports of booster effectiveness have been positive, the level of protection from booster vaccination is unclear. We conducted two studies to assess the impact of booster vaccination, with BNT162b2 or mRNA-1273, on the incidence of SARS-CoV-2 infection between August and December 2021. We first compared SARS-CoV-2 infection incidence in cohorts of 3-dose vaccine recipients to incidence in matched cohorts of 2-dose vaccine recipients (cohort size = 24,539 for BNT162b2 and 14,004 for mRNA-1273). Additionally, we applied a test-negative study design to compare the level of protection against symptomatic infection in 3-dose recipients to that observed in recent 2-dose primary vaccine series recipients. The 3-dose recipients experienced a significantly lower incidence rate of SARS-CoV-2 infection than the matched 2-dose cohorts (BNT162b2 Incidence Rate Ratio: 0.11, 95% CI: 0.09 to 0.13 and mRNA-1273 IRR: 0.11, 95% CI: 0.08 to 0.15). Results from the test-negative study showed the third vaccine dose mitigated waning of VE, with the risk of symptomatic infection in 3-dose recipients being comparable to that observed 7 to 73 days after the primary vaccine series. These results show that 3-dose vaccine regimens with BNT162b2 or mRNA-1273 are effective at reducing SARS-CoV-2 infection and support the widespread administration of booster vaccine doses.
Myeloproliferative neoplasms – a global view
Tefferi, Ayalew , Mathews, Vikram , Samuelsson, Jan , Szuber, Natasha , Xiao, Zhijian , Hokland, Peter , Ianotto, Jean-Christophe , Mathews, Vikram , Samuelsson, Jan , Szuber, Natasha , Hokland, Peter , Ianotto, Jean‐Christophe

Mayo Clinic

British Journal of Haematology | April 28, 2022 | Volume: 198 | Issue: 6 | Pages: 953-964

10.1111/bjh.18213 | PMID 35482584 Get It